SCS Capital Management LLC Invests $2.31 Million in Quanterix Corporation $QTRX

SCS Capital Management LLC acquired a new position in shares of Quanterix Corporation (NASDAQ:QTRX) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 354,339 shares of the company’s stock, valued at approximately $2,307,000. SCS Capital Management LLC owned about 0.91% of Quanterix at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. State of Wyoming purchased a new stake in shares of Quanterix during the 1st quarter worth approximately $47,000. Quantbot Technologies LP raised its position in Quanterix by 245.9% in the 1st quarter. Quantbot Technologies LP now owns 11,272 shares of the company’s stock valued at $73,000 after purchasing an additional 8,013 shares during the last quarter. Aaron Wealth Advisors LLC purchased a new stake in Quanterix in the 1st quarter valued at $79,000. Allspring Global Investments Holdings LLC purchased a new stake in Quanterix in the 1st quarter valued at $98,000. Finally, Cetera Investment Advisers purchased a new stake in Quanterix in the 4th quarter valued at $108,000. Hedge funds and other institutional investors own 86.48% of the company’s stock.

Quanterix Stock Performance

Shares of QTRX opened at $4.29 on Wednesday. The stock has a market capitalization of $199.36 million, a P/E ratio of -2.36 and a beta of 1.03. The company’s fifty day moving average is $5.34 and its two-hundred day moving average is $5.80. Quanterix Corporation has a 1 year low of $4.05 and a 1 year high of $15.85.

Quanterix (NASDAQ:QTRX) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.06). The firm had revenue of $24.48 million during the quarter, compared to analyst estimates of $29.73 million. Quanterix had a negative net margin of 56.04% and a negative return on equity of 18.41%. Quanterix has set its FY 2025 guidance at EPS. Sell-side analysts predict that Quanterix Corporation will post -0.98 EPS for the current year.

Insider Buying and Selling at Quanterix

In related news, Director David R. Walt purchased 123,990 shares of the stock in a transaction dated Friday, June 13th. The shares were acquired at an average cost of $6.14 per share, with a total value of $761,298.60. Following the purchase, the director directly owned 1,866,933 shares in the company, valued at $11,462,968.62. This trade represents a 7.11% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 6.80% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms recently commented on QTRX. Wall Street Zen downgraded shares of Quanterix from a “hold” rating to a “sell” rating in a research report on Thursday, May 22nd. Canaccord Genuity Group reiterated a “hold” rating and issued a $5.00 price target (down previously from $12.00) on shares of Quanterix in a research report on Monday, August 11th. One research analyst has rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $11.75.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.